+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Age Related Macular Degeneration - Pipeline Review, H1 2020

  • PDF Icon

    Drug Pipelines

  • 864 Pages
  • June 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5130324
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 21, 30, 33, 3, 169, 40 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 17 and 1 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Age Related Macular Degeneration - Overview
  • Age Related Macular Degeneration - Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics Assessment
  • Age Related Macular Degeneration - Companies Involved in Therapeutics Development
  • Age Related Macular Degeneration - Drug Profiles
  • Age Related Macular Degeneration - Dormant Projects
  • Age Related Macular Degeneration - Discontinued Products
  • Age Related Macular Degeneration - Product Development Milestones
  • Appendix

List of Tables
  • Number of Products under Development for Age Related Macular Degeneration, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Age Related Macular Degeneration - Pipeline by 3SBio Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Abpro Corp, H1 2020
  • Age Related Macular Degeneration - Pipeline by Abzyme Therapeutics LLC, H1 2020
  • Age Related Macular Degeneration - Pipeline by Active Biotech AB, H1 2020
  • Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H1 2020
  • Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Aerpio Pharmaceuticals Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Aevitas Therapeutics Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Affilogic SAS, H1 2020
  • Age Related Macular Degeneration - Pipeline by Aibios Co Ltd, H1 2020
  • Age Related Macular Degeneration - Pipeline by Aiviva BioPharma Inc, H1 2020
  • Age Related Macular Degeneration - Pipeline by Zhejiang Doer Biologics Corp, H1 2020
  • Age Related Macular Degeneration - Dormant Projects, H1 2020
  • Age Related Macular Degeneration - Discontinued Products, H1 2020

List of Figures
  • Number of Products under Development for Age Related Macular Degeneration, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3SBio Inc
  • 4D Molecular Therapeutics Inc
  • Abpro Corp
  • Abzyme Therapeutics LLC
  • Active Biotech AB
  • AdAlta Ltd
  • Adverum Biotechnologies Inc
  • Aerie Pharmaceuticals Inc
  • Aerpio Pharmaceuticals Inc
  • Aevitas Therapeutics Inc
  • Affilogic SAS
  • Aibios Co Ltd
  • Aiviva BioPharma Inc
  • Aldeyra Therapeutics Inc
  • Alexion Pharmaceuticals Inc
  • Alkahest Inc
  • Alkeus Pharmaceuticals Inc
  • Allegro Ophthalmics LLC
  • Allergan Ltd
  • Allgenesis Biotherapeutics Inc
  • Alpine Biotherapeutics Corp
  • Alteogen Inc
  • Alzheon Inc
  • Amarna Therapeutics BV
  • Amgen Inc
  • Amicogen Inc
  • Amyndas Pharmaceuticals LLC
  • AngioGenex Inc
  • Anida Pharma Inc
  • Annexon Inc
  • Apellis Pharmaceuticals Inc
  • Apexian Pharmaceuticals Inc
  • Apexigen Inc
  • Applied Genetic Technologies Corp
  • AptaBio Therapeutics Inc
  • Aptamer Sciences Inc
  • Ascentage Pharma Group International
  • Asclepiumm Taiwan Co Ltd
  • AsclepiX Therapeutics Inc
  • Astellas Pharma Inc
  • Avixgen Inc
  • Beijing Eastern Biotech Co Ltd
  • BellBrook Labs LLC
  • Beta Therapeutics Pty Ltd
  • Bio-Thera Solutions Ltd
  • BIOCND Inc
  • Biocure Technology Inc
  • Bioeq GmbH
  • Biogen Inc
  • Biokine Therapeutics Ltd
  • Biomics Biotechnologies Co Ltd
  • Biophytis SA
  • Boehringer Ingelheim International GmbH
  • Bridge Biotherapeutics Inc
  • Cadila Healthcare Ltd
  • Catalyst Biosciences Inc
  • CDR-Life Inc
  • Cell Care Therapeutics Inc
  • Cell Cure Neurosciences Ltd
  • Celon Pharma SA
  • Charlesson LLC
  • Chengdu Kanghong Pharmaceuticals Group Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • CHS Pharma Inc
  • Cinnagen Co
  • Clayton Biotechnologies Inc
  • Clearside BioMedical Inc
  • Clover Biopharmaceuticals
  • Coherus BioSciences Inc
  • CureLab Oncology Inc
  • Daiichi Sankyo Co Ltd
  • DNX Biopharmaceuticals Inc
  • Dobecure SL
  • Dong-A Socio Holdings Co Ltd
  • Drive Therapeutics LLC
  • EirGenix Inc
  • Elasmogen Ltd
  • Emerald Organic Products Inc
  • Envisia Therapeutics Inc
  • Enzene Biosciences Ltd
  • Epygen Biotech Pvt Ltd
  • Everglades Biopharma LLC
  • Exonate Ltd
  • Eye Co Pty Ltd
  • Eyedesis Biosciences LLC
  • EyeGate Pharmaceuticals Inc
  • EyePoint Pharmaceuticals Inc
  • Eyestem Research Pvt Ltd
  • Eyevensys SAS
  • F. Hoffmann-La Roche Ltd
  • Feramda Ltd
  • FirstString Research Inc
  • Formycon AG
  • Galimedix Therapeutics Ltd
  • Gemini Therapeutics Inc
  • Gene Signal International SA
  • Gene Techno Science Co Ltd
  • Genentech Inc
  • Generation Bio Co
  • Generium
  • Generoath Co Ltd
  • GenSight Biologics SA
  • Graybug Vision Inc
  • Gyroscope Therapeutics Ltd
  • Hanlim Pharm Co Ltd
  • HEALIOS KK
  • Hemera Biosciences Inc
  • Hengenix Biotech Inc
  • HK inno.N Corp
  • Huabo Biopharm Co Ltd
  • Huons Global Co Ltd
  • Ichor Therapeutics Inc
  • Iconic Therapeutics Inc
  • Ildong Pharmaceutical Co Ltd
  • Immupharma Plc
  • Inflammasome Therapeutics Inc
  • Innovent Biologics Inc
  • Ionis Pharmaceuticals Inc
  • Isarna Therapeutics GmbH
  • iTherapeutics Corp
  • iVeena Delivery Systems Inc
  • IVERIC bio Inc
  • Jeil Pharmaceutical Co Ltd
  • Johnson & Johnson
  • JW Pharmaceutical Corp
  • Kala Pharmaceuticals Inc
  • Kalos Therapeutics Inc
  • Katairo GmbH
  • Kodiak Sciences Inc
  • Kubota Vision Inc
  • Kuur Therapeutics Ltd
  • Kyowa Kirin Co Ltd
  • Lead Discovery Center GmbH
  • Lin Bioscience Inc
  • Lineage Cell Therapeutics Inc
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Mabion SA
  • MacuCLEAR Inc
  • maintect GmbH
  • Mediolanum farmaceutici SpA
  • MeiraGTx Holdings Plc
  • MetiMedi Pharmaceuticals Co Ltd
  • MitoImmune Therapeutics Inc
  • Mitotech SA
  • Mitsubishi Tanabe Pharma Corp
  • Mor Research Applications Ltd
  • Mperia Therapeutics Inc
  • NanoScope Technologies LLC
  • Nanoscope Therapeutics Inc
  • Neovacs SA
  • NeuExcell Therapeutics Inc
  • Nextgen Bioscience
  • NGM Biopharmaceuticals Inc
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Novelty Nobility Inc
  • Noveome Biotherapeutics Inc
  • OccuRx Pty Ltd
  • Ocugen Inc
  • Ocular Therapeutix Inc
  • OcuNexus Therapeutics Inc
  • ODIN Biotech Partners LLC
  • OliX Pharmaceuticals Inc
  • Omeros Corp
  • ONL Therapeutics Inc
  • Opthea Ltd
  • Outlook Therapeutics Inc
  • Oxford BioMedica Plc
  • Oxstem Ltd
  • Oxurion NV
  • PanOptica Inc
  • Paras Biopharmaceuticals Finland Oy
  • Pfizer Inc
  • Phanes Therapeutics Inc
  • PharmAbcine Inc
  • Phio Pharmaceuticals Corp
  • Phision Therapeutics
  • PlantForm Corp
  • Pleryon Therapeutics Ltd
  • Polus Inc
  • Profarma
  • Qilu Pharmaceutical Co Ltd
  • Reflexion Pharmaceuticals Inc
  • Regen BioPharma Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • Reliance Life Sciences Pvt Ltd
  • RemeGen Ltd
  • Retrotope Inc
  • RheinCell Therapeutics GmbH
  • Ribomic Inc
  • RiniSight Inc
  • Ripple therapeutics Corp
  • Samjin Pharm Co Ltd
  • Samsung Bioepis Co Ltd
  • SanBio Company Limited
  • SciFluor Life Sciences LLC
  • Semathera Inc
  • Senju Pharmaceutical Co Ltd
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai United Cell Biotechnology Co Ltd
  • Sigilon Therapeutics Inc
  • SiNOPSEE Therapeutics Pte Ltd
  • Splash Pharmaceuticals Inc
  • Stealth BioTherapeutics Corp
  • Stuart Therapeutics Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Surrozen Inc
  • Sustained Nano Systems LLC
  • Suzhou Kintor Pharmaceutical Inc
  • Suzhou Stainwei Biotech Inc
  • Sylentis SAU
  • TaeJoon Pharmaceuticals Co Ltd
  • Tarsius Pharma Ltd
  • TechnoPhage SA
  • Topadur Pharma AG
  • TOT Biopharm Co Ltd
  • Translatum Medicus Inc
  • TreeFrog Therapeutics SAS
  • Visgenx Inc
  • Wellstat Ophthalmics Corp
  • Xbrane Biopharma AB
  • Xcovery Holding Co LLC
  • YD Life Science Co
  • Zhejiang Doer Biologics Corp